Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand.

•Of patients surviving >24 months after antibodies to programmed death-1 receptor and its receptor therapy, most had durable benefit.•Health-related quality of life outcomes compared favourably to unselected cancer cohorts.•Chronic immune-related adverse events may be more common than previously thought.•No obvious long-term adverse cardiometabolic signals were noted.